Etidronate for treatment of osteoporosis

Shogo Asano, Atsushi Suzuki, Mitsuyasu Itoh

Research output: Contribution to journalReview article

Abstract

The treatment with anti-resorptive agents including bisphosphonates and selective estrogen receptor modulators (SERM) has clinical relevance to reduce osteoporotic fractures in postmenopausal women. Among them, etidronate has a unique mechanism to suppress osteoclastic activity, and could be used to treat long-term immobilized patients, to whom other bisphosphonates or SERM are not available because of their adverse effects. In addition, intermittent therapy regimen (two weeks every three months) and less gastroesophageal reflux disorder may be suitable for some patients. Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients.

Original languageEnglish
Pages (from-to)938-942
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume67
Issue number5
Publication statusPublished - 01-01-2009

Fingerprint

Etidronic Acid
Selective Estrogen Receptor Modulators
Diphosphonates
Osteoporosis
Osteoporotic Fractures
Gastroesophageal Reflux
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Asano, Shogo ; Suzuki, Atsushi ; Itoh, Mitsuyasu. / Etidronate for treatment of osteoporosis. In: Nippon rinsho. Japanese journal of clinical medicine. 2009 ; Vol. 67, No. 5. pp. 938-942.
@article{1f7027dfdece4ffb99fe3d70538651d3,
title = "Etidronate for treatment of osteoporosis",
abstract = "The treatment with anti-resorptive agents including bisphosphonates and selective estrogen receptor modulators (SERM) has clinical relevance to reduce osteoporotic fractures in postmenopausal women. Among them, etidronate has a unique mechanism to suppress osteoclastic activity, and could be used to treat long-term immobilized patients, to whom other bisphosphonates or SERM are not available because of their adverse effects. In addition, intermittent therapy regimen (two weeks every three months) and less gastroesophageal reflux disorder may be suitable for some patients. Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients.",
author = "Shogo Asano and Atsushi Suzuki and Mitsuyasu Itoh",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "67",
pages = "938--942",
journal = "Nippon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "5",

}

Etidronate for treatment of osteoporosis. / Asano, Shogo; Suzuki, Atsushi; Itoh, Mitsuyasu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 67, No. 5, 01.01.2009, p. 938-942.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Etidronate for treatment of osteoporosis

AU - Asano, Shogo

AU - Suzuki, Atsushi

AU - Itoh, Mitsuyasu

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The treatment with anti-resorptive agents including bisphosphonates and selective estrogen receptor modulators (SERM) has clinical relevance to reduce osteoporotic fractures in postmenopausal women. Among them, etidronate has a unique mechanism to suppress osteoclastic activity, and could be used to treat long-term immobilized patients, to whom other bisphosphonates or SERM are not available because of their adverse effects. In addition, intermittent therapy regimen (two weeks every three months) and less gastroesophageal reflux disorder may be suitable for some patients. Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients.

AB - The treatment with anti-resorptive agents including bisphosphonates and selective estrogen receptor modulators (SERM) has clinical relevance to reduce osteoporotic fractures in postmenopausal women. Among them, etidronate has a unique mechanism to suppress osteoclastic activity, and could be used to treat long-term immobilized patients, to whom other bisphosphonates or SERM are not available because of their adverse effects. In addition, intermittent therapy regimen (two weeks every three months) and less gastroesophageal reflux disorder may be suitable for some patients. Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients.

UR - http://www.scopus.com/inward/record.url?scp=67649195265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649195265&partnerID=8YFLogxK

M3 - Review article

VL - 67

SP - 938

EP - 942

JO - Nippon rinsho. Japanese journal of clinical medicine

JF - Nippon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 5

ER -